Clinical Cancer Research Meeting Calendar Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, G.-J.
Right arrow Articles by Takenoshita, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, G.-J.
Right arrow Articles by Takenoshita, S.
Clinical Cancer Research Vol. 5, 2971-2977, October 1999
© 1999 American Association for Cancer Research

Cancer Biology, Immunology, Cytokines

Tamoxifen-induced Apoptosis in Breast Cancer Cells Relates to Down-Regulation of bcl-2, but not bax and bcl-XL, without Alteration of p53 Protein Levels1

Guo-Jun Zhang2, Izo Kimijima, Masamitsu Onda, Masahiko Kanno, Hisayoshi Sato, Takanori Watanabe, Atsuo Tsuchiya, Rikiya Abe and Seiichi Takenoshita

Department of Surgery II [G. J. Z., I. K., M. O., M. K., H. S., T. W., A. T., S. T.], Fukushima Medical University School of Medicine, Ohara Research Institute [R. A.], Ohara General Hospital, Fukushima 960-1295, Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Tamoxifen (TAM) has been shown to induce apoptosis in breast cancer cells. bcl-2 family genes, which can interact with each other, have been shown to interfere with apoptosis after various stimuli. In this study, we investigated the effects of TAM on bcl-2 family gene products bcl-2, bax, and bcl-XL and on p53 levels in estrogen receptor-positive MCF-7 breast cancer cells. We found that TAM induced time- and concentration-dependent down-regulation of bcl-2 at both the mRNA and protein level. Down-regulation of bcl-2 correlated with TAM-induced apoptosis. In addition, estradiol treatment significantly increased bcl-2 protein expression and blocked the reduction of bcl-2 by TAM. TAM did not, however, affect bax, bcl-XL, or p53 expression at the mRNA or protein level. Our results demonstrate that TAM can induce apoptosis in a time- and dose-dependent manner by modulating bcl-2 levels in breast cancer cells, and down-regulation of bcl-2 induced by TAM was not accompanied by alterations in p53 levels.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
TAM3 is commonly used for adjuvant therapy of breast cancer and is a key drug for chemoprevention of breast cancer in high-risk women (1, 2, 3) . TAM is believed to inhibit the growth of breast cancer mainly through competing with estrogen for ER binding. The mechanism of action of TAM remains unclear, although its breast cancer antiproliferative effect may be via a receptor-mediated cytostatic activity, a nonspecific activity, or a receptor-mediated cytotoxic activity. Previous reports have suggested that TAM induced characteristic morphological changes consistent with apoptosis, including condensation of cytoplasm and convolution of nuclear and internucleosomal DNA fragmentation in breast cancer cells (4, 5, 6) . This suggests that TAM inhibits the growth of breast cancer by inducing apoptosis.

The bcl-2 gene, which was isolated by its juxtaposition to the immunoglobulin heavy chain locus in follicular lymphoma, codes a Mr 26,000 protein that inhibits apoptosis (7) . Recently, several bcl-2 family genes have been identified by their homology with bcl-2 (8) . Some bcl-2 family members are inhibitors of apoptosis, including bcl-2 (9) , bcl-XL (10) , BAG-1 (11) , and mcl-1 (12) , whereas others are inducers of cell death, including bax (13) , bad (14) , and bcl-XS (15) . These members interact with each other via their BH3 domain in an antagonistic fashion to regulate apoptosis. Apoptosis is controlled by the ratio of various bcl-2 family members (16) . When levels of apoptosis promoters (bax and bcl-XS) increase, apoptosis is accelerated, whereas when the inhibitors of apoptosis (bcl-2 and bcl-XL) increase, the cells are predisposed to be resistant to apoptosis in response to external stimuli. Previous reports have demonstrated that changes in the ratio of protoapoptotic to antiapoptotic proteins result in susceptibility to apoptosis, and a high bax:bcl-2 ratio has been found to correlate with etoposide-induced apoptosis (17) . It has been suggested that estrogen enhances resistance to chemotherapy drugs such as Taxol and cisplatin by increasing the bcl-2:bax ratio (18 , 19) . Overexpression of HER2 in MCF-7 cells has been shown to suppress TAM-induced apoptosis by up-regulating bcl-2 and bcl-XL protein (20) . However, whether TAM directly modulates bcl-2, bax, or bcl-XL expression is not known. On the other hand, p53 can modulate susceptibility to cytotoxic drugs by inducing apoptosis (17) . Expression of p53 is up-regulated after DNA damage, such as by radiation or cytotoxic chemotherapy. In addition, wild-type p53 has been shown to induce apoptosis by increasing levels of bax and decreasing levels of bcl-2 (21) . However, p53 is not present for all instances of apoptosis, and the effects of TAM on p53 have not been examined.

In the present study, we investigated whether TAM-induced apoptosis is related to the expression of bcl-2 family genes and p53 protein. We tested TAM-induced apoptotic activity and examined the effects of TAM on bcl-2 family genes (bcl-2, bax, and bcl-XL) and p53 in MCF-7 breast cancer cells. We found that TAM-induced apoptosis is accompanied by down-regulation of bcl-2 levels without alterations in p53 in breast cancer cells.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture and Reagents.
MCF-7 human breast cancer cells, which are ER positive, were obtained from the ATCC (Rockville, MD). The cells were maintained in DMEM with 10% FBS at 37°C in a humidified incubator and 5% CO2. Cells were grown to confluence and passaged with the use of trypsin-EDTA. For apoptosis experiments, cells at approximately 2 x 106 cells/75 cm2 flask were placed in phenol red-free DMEM with 10% DCC-FBS to remove steroids (22) . In this study, the concentration of estradiol in DCC-FBS was undetectable (<=8 pg/ml) by using the estradiol detection kit (Diagnostic Products Corp., Los Angeles, CA), whereas FBS contained 29 pg/ml of estradiol. After 48 h incubation, the culture medium was removed, and new medium containing TAM was added. TAM and E2 were purchased from Sigma Chemical Co. (St. Louis, MO) and dissolved in ethanol as a 10-2 stock solution.

Quantitation of Apoptotic Cells by ELISA.
For quantitation of apoptosis induced by TAM, we used a cell death detection ELISAplus kit (Boehringer-Mannheim, Mannheim, Germany) to measure cytoplastic DNA-histone complexes generated during apoptotic DNA fragmentation, as described previously (20) . Each experiment was performed in triplicate. Absorbance at 405 nM was measured using a microplate autoreader, and the results are expressed as the enrichment factor relative to the untreated controls.

RT-PCR Analyses of bcl-2, bax, and bcl-X mRNA Levels.
Semiquantitation of bcl-2, bax, and bcl-X mRNA levels were performed using RT-PCR. Total cellular RNA was isolated using the Trizol reagent according to the manufacturer’s instructions. (Life Technologies, Inc.). One µg of RNA was used for cDNA synthesis by using the First Strand cDNA Synthesis kit (Pharmacia Biotech, Uppsala, Sweden). A typical PCR consisted of 5 µl of cDNA, 0.2 mM deoxynucleotide triphosphate, 1 µM of each primer, 1x PCR buffer, and 2.5 units of Taq polymerase. The PCR profile was 95°C for 40 s, 65°C for 40 s, and 72°C for 2 min for 35 cycles, followed by extension for 7 min at 72°C. The primer pairs used in this study for PCR amplification were as follows: bcl-2 (459 bp), upstream 5'-GGTGCCACCTGTGGTCCACCTG-3' and downstream 5'-CTTCACTTGTGGCCCAGATAGG-3'; bax (538 bp), upstream 5'-CAGCTCTGAGCAGATCATGAAGACA-3' and downstream 5'-GCCCATCTTCTTCCAGATGGTGAGC-3'; bcl-XL (780 bp), upstream 5'-TTGGACAATGGACTGGTTGA-3' and downstream 5'-GTAGAGTGGATGGTCAGTG-3'; and {beta}-actin (838 bp), upstream 5'-ATCTGGCACCACACCTTCTACAATGAGCTGCG-3' and downstream 5'-CGT-CATACTCCTGCTTGCTGATCCACATCTGC-3'. After PCR, aliquots of the reactions were analyzed on 2% agarose gels and visualized using ethidium bromide. The amount of mRNA was semiquantitated by comparing relative intensities of the amplified {beta}-actin to an equal amount of cDNA.

Western Blot Analyses.
Total proteins was extracted from approximately 5 x 106 cells treated with TAM for up to 72 h. Briefly, cells were washed with ice-cold PBS and lysed in 50 mM Tris (pH 7.6), 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP40, 10 µg/ml phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, and 0.02% sodium azide for 30 min at 4°C. Insoluble material was removed by centrifugation at 12,000 x g for 15 min. Equal amounts of proteins were size fractionated under denaturing conditions on 12.5% SDS-polyacrylamide gels and transferred to Clearblot P membranes (Atto, Tokyo, Japan). The membranes were probed with anti-bcl-2 (clone 124; Dako, Glostrup, Denmark), anti-bax (MBL, Nagoya, Japan), anti-bcl-XL (Transduction Laboratories, Lexington, KY), or anti-p53 antibody (PAb1801; Oncogene Science, Cambridge, MA) as described previously (23) and were reprobed with {beta}-actin antibody (Oncogene Science) as an internal control.

Statistical Analysis.
Densitometry was performed using NIH image 1.59 software (National Cancer Institute, Bethesda, MD). The intensities of the protein or mRNA bands were normalized to the actin bands and quantified by comparing with those of control cells. Statistical differences were evaluated by Student’s paired t test. P < 0.05 was considered as statistically significant.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
TAM-induced Apoptosis Is Time- and Concentration-dependent.
Cells grown on plastic flasks in DMEM with 10% DCC-FBS displayed typical epithelial patterns: a cluster of cells growing in a polygonal shape (Fig. 1A)Citation . Within 48 h of treatment with 10-5 TAM, MCF-7 cells showed a marked change in morphology, including shrinkage, irregular shape and condensed chromatin in the nuclei (Fig. 1B)Citation . ELISA revealed that more than 10-8M TAM had apoptotic effects on breast cancer cells (Fig. 2)Citation . Furthermore, TAM induced apoptosis in a time- and concentration-dependent manner. When treated with 10-5M TAM for 72 h, the cells exhibited an ~8-fold higher apoptosis rate than untreated cells (P < 0.0001).



View larger version (118K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Effect of TAM on morphology of MCF-7 breast cancer cells (phase-contrast microscopy). A, untreated cells cultured in DMEM with 10% DCC-FBS. B, cells were treated with 10-5M TAM for 48 h.

 


View larger version (47K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Relative apoptosis induced by TAM as determined by ELISA (see "Materials and Methods"). The enrichment factor was calculated as the ratio of absorbance of the treated cells to that of untreated cells. Bars, SD.

 
Effects of TAM on Expression of bcl-2, bax, and bcl-XL mRNA.
To determine the effects of TAM on the expression of bcl-2, bax, and bcl-XL mRNA in MCF-7 cells, we performed RT-PCR. TAM (10-8M or more) decreased the bcl-2 mRNA levels in MCF-7 cells after 48 h exposure, and the decrease of bcl-2 mRNA was dose dependent (Fig. 3A)Citation . In addition, TAM treatment down-regulated bcl-2 mRNA expression in a time-dependent manner; the reduction of bcl-2 was by ~70% after 72 h exposure to 10-5M TAM (Fig. 3B)Citation . There was no significant difference in either bax or bcl-XL mRNA levels before and after TAM treatment (data not shown).



View larger version (82K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Effects of TAM on bcl-2 mRNA levels. Cells exposed to TAM at the indicated concentration (B) and cultured in 10-5M TAM for up to 72 h (A) were subjected to RT-PCR as described in "Materials and Methods."

 
Effects of TAM on Expression of bcl-2, bax, and bcl-XL Proteins.
To determine the effects of TAM on the expression of bcl-2, bax, and bcl-XL proteins in MCF-7 cells, we performed Western blotting analysis. After 48 h of treatment, 10-10 TAM caused a slight but not significant increase in bcl-2 protein. TAM (10-8M or more) caused reduction in bcl-2 protein expression, 10-5M TAM caused a 70% reduction compared with nontreatment cells (Fig. 4A)Citation . TAM had a concentration-dependent effect on bcl-2 protein (Fig. 4B)Citation . We failed to observe a phosphorylated isoform of bcl-2 protein in the Western blots. In addition, exposure to TAM did not alter expression of bax or bcl-XL proteins in MCF-7 cells (data not shown).



View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Effects of TAM on bcl-2 protein in MCF-7 cells. A, cells were treated with TAM at the concentrations indicated at the top of the lanes for 48 h and subjected to Western blotting as described in "Materials and Methods." B, bcl-2 bands were quantified using NIH image software and normalized to actin bands. Data are shown as the means of three separate experiments; bars, SD.

 
To investigate whether the effects of TAM on bcl-2 levels are time dependent, we added TAM to MCF-7 cells at a final concentration of 10-5M for up to 72 h. After 48–72 h treatment, an ~80% reduction in bcl-2 protein was detected (Fig. 5A)Citation . TAM at a concentration of 10-5M down-regulated bcl-2 protein levels in a time-dependent manner (Fig. 5B)Citation . Furthermore, this down-regulation in bcl-2 protein correlated with apoptosis detected by ELISA (Fig. 2)Citation . However, no significant changes in either bax or bcl-XL expression were detected (Fig. 6)Citation .



View larger version (35K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Expression of bcl-2 protein levels in MCF-7 cells after treatment with 10-5M TAM for up to 72 h. A, cells were exposed to 10-5M TAM for the times indicated and subjected to Western blotting as described in "Materials and Methods." B, bcl-2 bands were quantified using NIH image software and normalized to actin bands. Data are shown as the means of three separate experiments; bars, SD.

 


View larger version (57K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Effects of TAM on bax and bcl-XL protein in MCF-7 cells after treatment with 10-5M TAM for up to 72 h. Total protein were prepared from cells that were exposed to 10-5M TAM for the times indicated above each lane.

 
We also tested the effects of E2 on TAM-induced apoptosis by adding 10-8M E2 with TAM. We found that addition of E2 blocked TAM induced apoptosis (Fig. 7A)Citation . E2 significantly increased bcl-2 protein levels with 10-8M E2, causing 4.3-fold increase in bcl-2 protein levels (Fig. 7B)Citation . Moreover, E2 blocked the reduction of bcl-2 induced by TAM.



View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 7. Effects of E2 on TAM-induced apoptosis and bcl-2 protein in MCF-7 cells. A, relative apoptosis as determined by ELISA (see "Materials and Methods"). Bars, SD. B, Western blotting of bcl-2 protein. Cells were exposed to basic medium (Lane 1), 10-8M E2 (Lane 2), 10-8M E2 and 10-6M TAM (Lane 3), and 10-6M TAM (Lane 4) for 48 h.

 
Effects of TAM on p53 Expression.
We determined the effects of TAM on p53 protein expression by Western blotting analysis. As shown in Fig. 8Citation , no differences in p53 protein levels were found between untreated cells and those treated with 10-5M for up to 72 h. Also, 10-10 to 10-6M TAM did not affect wild-type p53 levels (data not shown).



View larger version (64K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 8. Effects of TAM on p53 protein levels in MCF-7 cells. Cells were treated with 10-5M TAM for up to 72 h and subjected to Western blotting as described in "Materials and Methods."

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this study, we demonstrated that TAM, an antiestrogen, induces apoptosis in MCF-7 human breast cells in a time- and concentration-dependent manner, which is consistent with previous reports (5) . bcl-2 plays an important role in the inhibition of apoptosis stimulated by various factors, such as irradiation, chemotherapeutic drugs, and withdrawal of growth factors (24 , 25) . Our results demonstrate that expression of bcl-2 is down-regulated in MCF-7 cells after culture with more than 10-8M TAM at both the mRNA and protein levels. In contrast to our data, a previous report did not find an effect of 10-9 to 10-7M TAM on bcl-2 protein levels in MCF-7 cells. Very recently, Burow et al. (26) have reported that three different MCF-7 cells from different laboratories show different sensitivities to tumor necrosis factor-{alpha}-induced apoptosis. In their study, MCF-7 N (from ATCC) demonstrated a higher sensitivity than the other two variants of MCF-7 and showed internucleosomal DNA fragmentation. Thus, the discrepancy between Huang’s and our report might be attributable to the difference between the characters of these two MCF-7 cell lines, although both of them were obtained from ATCC. Moreover, the down-regulation of bcl-2 caused by TAM is time and concentration dependent and correlated with TAM-induced apoptosis. These observations strongly suggest that down-regulation of bcl-2 plays a critical role in deregulation of apoptosis inhibition and also triggers apoptosis by TAM.

Whether cells enter apoptosis is determined by the ratio of proapoptotic:antiapoptotic factors. We did not find any alterations in bax and bcl-XL expression after TAM treatment. This conflicts with a report that ionizing radiation induces down-regulation of bcl-XL mRNA expression (27) and suggests that alteration of bcl-2 protein alone is sufficient to alter the bax:bcl-2 ratio or decrease the antiapoptotic levels and alter susceptibility to apoptosis. However, it is also possible that other members of the bcl-2 family, e.g., BAG-1 (11) and bad (14) , may interfere with TAM-induced apoptosis rather than bax or bcl-XL.

Taxol, which activates a mitogen-stimulated protein serine/threonine kinase (i.e., c-Raf-1; Ref. 28 ), has been shown to induce apoptosis via phosphorylating bcl-2 protein in breast and prostate cancers (23 , 29) . TAM could not phosphorylate bcl-2 protein in MCF-7 cells. Thus, apoptosis induced by TAM is not due to a functional inactivation by phosphorylation of bcl-2 protein.

The mechanism whereby TAM down-regulates bcl-2 expression remains unknown. In breast carcinomas, bcl-2 has been shown to associate with ER status (30) . Thus, bcl-2 may be regulated through the interaction of estrogen with ER (18) . Furthermore, in MCF-7 cells, estrogen has been shown to inhibit cytotoxic drug-induced apoptosis through up-regulating bcl-2 levels (31) . A previous study demonstrated that MCF-7 cells cultured in a medium containing 10% FBS express significantly higher bcl-2 levels than those cells exposed to estrogen-free medium for 14 days (18) . This result suggests that estrogen contained in 10% FBS medium has a role in up-regulating bcl-2 levels. To eliminate the effect of endogenous estrogen, a medium with 10% DCC-FBS was used to investigate the effect of E2 and TAM on bcl-2 levels. In our present study, 10-8M E2 significantly increased bcl-2 protein and blocked TAM-induced apoptosis. These results are consistent with a previous report that >10-9M E2 up-regulated bcl-2 levels in MCF-7 cells exposed to an estrogen-free medium for 4–14 days, and TAM reduced the rate of increase of bcl-2 levels (18) . We have demonstrated that down-regulation of bcl-2 is associated with the apoptotic action of TAM. These data, along with previous reports, strongly suggest that down-regulation of bcl-2 is necessary for TAM-induced apoptosis and appears to be mediated by interaction between TAM and ER. The decrease in both mRNA and protein levels induced by TAM suggest that TAM acts via a transcriptional mechanism. It appears that the E2-ER complex can directly bind to the estrogen response element of the bcl-2 promoter. However, no consensus sequence (GGTCA-nnn-TGACC) for the estrogen response element has been clarified in the bcl-2 gene sequence (32) . Dubik and Shiu (33) have localized a 116-bp region overlapping the P2 promoter in the human c-myc gene, which lacks the conventional estrogen response element sequence. They have also shown that estrogen activates c-myc expression via the interaction of E2-ER complex with the 116-bp regions. Thus, further study is needed to clarify whether an alternative sequence conferring estrogen responsiveness exists in the bcl-2 gene as in the c-myc oncogene.

bcl-2 expression may be down-regulated by p53 through binding to the silencer of bcl-2 (34) , and p53 plays a critical role in apoptosis after treatment with cytotoxic agents or irradiation. To discover whether bcl-2 down-regulation is caused via a p53-mediated pathway, we examined the effects of TAM on p53 protein in MCF-7 cells. We did not find increases in p53 protein expression. Although in testicular tumors and other tumors p53 has been found to increase severalfold after treatment with cytotoxic agents, this is not the case for all of cell lines or all types of DNA damage (35 , 36) . Our results demonstrate that TAM-induced apoptosis is probably not mediated by altering p53 levels. Similarly, in MCF-7 breast cancer cells exposed to hypoxia, no changes in p53 protein were found compared with cells under aerobic conditions, and only 50% of cells undergoing apoptosis were shown to be p53 positive (37) . p53 is both a transactivator and a repressor of transcription, but it remains unclear whether the activities of p53 are required for apoptosis. Previous investigation indicated that p53-mediated apoptosis initiated by DNA damage can occur in the presence of actinomycin D or cycloheximide (36) , which blocks RNA or protein synthesis. Taken together with our observations, this suggests that functional p53 might play a role in the regulation of apoptosis by TAM rather than through an elevation in p53 levels, and p53 may initiate apoptosis by a p53 activity not requiring transcription in breast cancer cells.

In breast cancers, bcl-2 expression has been shown to be a favorable prognostic factor and predictor of response to endocrine therapy (38, 39, 40) . This improved response to endocrine therapy by bcl-2-positive tumors might be the result of down-regulation of bcl-2 by antiestrogen agents, with the resultant susceptibility to apoptosis. Our results provide a possible explanation for these clinical observations, showing that TAM can trigger apoptosis by down-regulating bcl-2 levels, control tumor progression, and improve prognosis of bcl-2-positive tumors. Thus, treatment modulating apoptosis may benefit breast cancer patients. Recently, several studies in vitro have showed that antisense oligodeoxynucleotide targeting the bcl-2 coding sequence can effectively reduce the viability of malignant cells by down-regulating bcl-2 levels in both small lung cancer and hematological malignancies (41 , 42) . Antisense therapy to reduce bcl-2 expression may provide a novel therapeutic strategy (43) and enhance the antitumor effects of TAM in bcl-2-positive breast cancers.

In conclusion, our results demonstrate that TAM can induce apoptosis in a time- and dose-dependent manner by modulating bcl-2 levels in breast cancer cells. The reduction of bcl-2 induced by TAM is likely regulated at the transcriptional level and is not accompanied by alterations in p53 levels. Further studies should be performed to investigate whether TAM effects on apoptosis and bcl-2 expression in MCF-7 cells can be extended to other antiestrogens or whether TAM can induce apoptosis and down-regulate bcl-2 levels in other ER-positive breast cancer cell lines.


   ACKNOWLEDGMENTS
 
We thank Masao Kato for photography and Yayoi Mori, Takako Kanno, and Teiko Suzuki for excellent technical assistance. We are also grateful to Reina Yamamoto and Junko Watanabe for preparing the manuscript.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by a Grant-in-Aid for General Science Research from the Ministry of Education, Science and Culture of Japan and in part by a grant from the Foundation for the Promotion of Fukushima Medicine, Japan. Back

2 To whom requests for reprints should be addressed, at Department of Surgery II, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Japan. Phone: 81-24-5482111, extension 2342; Fax: 81-24-5483249; E-mail: zhang{at}cc.fmu.ac.jp Back

3 The abbreviations used are: TAM, tamoxifen; ER, estrogen receptor; ATCC, American Type Culture Collection; FBS, fetal bovine serum; DCC-FBS, dextran-coated charcoal treated FBS; E2, 17{beta}-estradiol; RT-PCR, reverse-transcription PCR. Back

Received 11/ 4/98; revised 6/ 7/99; accepted 6/ 7/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Tormey, D. C., Gray, R., and Falkson, H. C. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group [see comments]. J. Natl. Cancer Inst., 88: 1828–1833, 1996.
  2. Rutqvist, L. E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T., and Wilking, N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group [see comments]. J. Natl. Cancer Inst., 87: 645–651, 1995.
  3. Nayfield S. G. Tamoxifen’s role in chemoprevention of breast cancer: an update. J. Cell Biochem. Suppl., 22: 42-50, 1995.[Medline]
  4. Frankfurt O. S., Sugarbaker E. V., Robb J. A., Villa L. Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. Cancer Lett., 97: 149-154, 1995.[Medline]
  5. Perry R. R., Kang Y., Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann. Surg. Oncol., 2: 238-245, 1995.[Abstract]
  6. Kang, Y., Cortina, R., and Perry, R. R. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells [see comments]. J. Natl. Cancer Inst., 88: 279–284, 1996.
  7. Tsujimoto Y., Finger L. R., Yunis J., Nowell P. C., Croce C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science (Washington DC), 226: 1097-1099, 1984.[Abstract/Free Full Text]
  8. Reed J. C., Miyashita T., Takayama S., Wang H. G., Sato T., Krajewski S., Aime-Sempe C., Bodrug S., Kitada S., Hanada M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell Biochem., 60: 23-32, 1996.[Medline]
  9. Reed J. C. Bcl-2 and the regulation of programmed cell death. J.Cell Biol., 124: 1-6, 1994.[Free Full Text]
  10. Gonzalez-Garcia M., Perez-Ballestero R., Ding L., Duan L., Boise L. H., Thompson C. B., Nunez G. bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development (Camb.), 120: 3033-3042, 1994.[Abstract]
  11. Takayama S., Sato T., Krajewski S., Kochel K., Irie S., Millan J. A., Reed J. C. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell, 80: 279-284, 1995.[Medline]
  12. Reynolds J. E., Yang T., Qian L., Jenkinson J. D., Zhou P., Eastman A., Craig R. W. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res., 54: 6348-6352, 1994.[Abstract/Free Full Text]
  13. Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius V. M., Niskanen E., Nordling S., Reed J. C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res., 55: 4471-4478, 1995.[Abstract/Free Full Text]
  14. Yang E., Zha J., Jockel J., Boise L. H., Thompson C. B., Korsmeyer S. J. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell, 80: 285-291, 1995.[Medline]
  15. Minn A. J., Boise L. H., Thompson C. B. Bcl-x(S) antagonizes the protective effects of Bcl-x(L). J. Biol Chem., 271: 6306-6312, 1996.[Abstract/Free Full Text]
  16. Reed J. C., Miyashita T., Takayama S., Wang H. G., Sato T., Krajewski S., Aime-Sempe C., Bodrug S., Kitada S., Hanada M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell Biochem., 60: 23-32, 1996.
  17. Chresta C. M., Masters J. R., Hickman J. A. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax: Bcl-2 ratio. Cancer Res., 56: 1834-1841, 1996.[Abstract/Free Full Text]
  18. Huang Y., Ray S., Reed J. C., Ibrado A. M., Tang C., Nawabi A., Bhalla K. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res. Treat., 42: 73-81, 1997.[Medline]
  19. Wang T. T., Phang J. M. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res., 55: 2487-2489, 1995.[Abstract/Free Full Text]
  20. Kumar R., Mandal M., Lipton A., Harvey H., Thompson C. B. Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin. Cancer Res., 2: 1215-1219, 1996.[Abstract]
  21. Miyashita T., Krajewski S., Krajewska M., Wang H. G., Lin H. K., Liebermann D. A., Hoffman B., Reed J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.[Medline]
  22. Germain P., Harbrioux G. Modulation of the estradiol-17{beta} mitogenic effect on human breast cancer MCF-7 cells by serum albumin in defined medium. Anticancer Res., 13: 1581-1585, 1993.[Medline]
  23. Haldar S., Chintapalli J., Croce C. M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 56: 1253-1255, 1996.[Abstract/Free Full Text]
  24. Miyashita T., Reed J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151-157, 1993.[Abstract/Free Full Text]
  25. Jaattela M., Benedict M., Tewari M., Shayman J. A., Dixit V. M. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene, 10: 2297-2305, 1995.[Medline]
  26. Burow M. E., Weldon C. B., Tang Y., Navar G. L., Krajewski S., Reed J. C., Hammond T. G., Clejan S., Beckman B. S. Differences in susceptibility to tumor necrosis factor {alpha}-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res., 58: 4940-4946, 1998.[Abstract/Free Full Text]
  27. Chen M., Quintans J., Fuks Z., Thompson C., Kufe D. W., Weichselbaum R. R. Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor {alpha}, and ceramide. Cancer Res., 55: 991-994, 1995.[Abstract/Free Full Text]
  28. Wang, H. G., Rapp, U. R., and Reed, J. C. Bcl-2 targets the protein kinase Raf-1 to mitochondria [see comments]. Cell, 87: 629–638, 1996.
  29. Blagosklonny M. V., Schulte T., Nguyen P., Trepel J., Neckers L. M. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res., 56: 1851-1854, 1996.[Abstract/Free Full Text]
  30. Zhang G. J., Kimijima I., Abe R., Kanno M., Katagata N., Hara K., Watanabe T., Tsuchiya A. Correlation between the Expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas. Clin. Cancer Res., 3: 2329-2336, 1997.[Abstract/Free Full Text]
  31. Teixeira C., Reed J. C., Pratt M. A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res., 55: 3902-3907, 1995.[Abstract/Free Full Text]
  32. Seto M., Jaeger U., Hockett R. D., Graninger W., Bennett S., Goldman P., Korsmeyer S. J. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J., 7: 123-131, 1988.[Medline]
  33. Dubik D., Shiu R. P. C. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene, 7: 1587-1594, 1992.[Medline]
  34. Haldar S., Negrini M., Monne M., Sabbioni S., Croce C. M. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res., 54: 2095-2097, 1994.[Abstract/Free Full Text]
  35. Sakamuro D., Eviner V., Elliott K. J., Showe L., White E., Prendergast G. C. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene, 11: 2411-2418, 1995.[Medline]
  36. Caelles, C., Helmberg, A., and Karin, M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes [see commentsrsqb;. Nature (Lond.), 370: 220–223, 1994.
  37. Amellem O., Stokke T., Sandvik J. A., Smedshammer L., Pettersen E. O. Hypoxia-induced apoptosis in human cells with normal p53 status and function, without any alteration in the nuclear protein level. Exp. Cell Res., 232: 361-370, 1997.[Medline]
  38. Gee J. M., Robertson J. F., Ellis I. O., Willsher P., McClelland R. A., Hoyle H. B., Kyme S. R., Finlay P., Blamey R. W., Nicholson R. I. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer, 59: 619-628, 1994.[Medline]
  39. Silvestrini R., Benini E., Veneroni S., Daidone M. G., Tomasic G., Squicciarini P., Salvadori B. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J. Clin. Oncol., 14: 1604-1610, 1996.[Abstract/Free Full Text]
  40. Zhang G. J., Tsuda H., Adachi I., Fukutomi T., Yamamoto H., Hirohashi S. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins. Jpn. J. Clin. Oncol., 27: 371-377, 1997.[Abstract/Free Full Text]
  41. Kitada S., Takayama S., De Riel K., Tanaka S., Reed J. C. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. Dev., 4: 71-79, 1994.[Medline]
  42. Ziegler A., Luedke G. H., Fabbro D., Altmann K. H., Stahel R. A., Zangemeister-Writtke U. Induction of apoptosisin small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J. Natl. Cancer Inst., 89: 1027-1036, 1997.[Abstract/Free Full Text]
  43. Reed J. C. Promise and problems of bcl-2 antisense therapy. J. Natl. Cancer Inst., 89: 988-990, 1997.[Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
A. Naresh, A. D. Thor, S. M. Edgerton, K. C. Torkko, R. Kumar, and F. E. Jones
The HER4/4ICD Estrogen Receptor Coactivator and BH3-Only Protein Is an Effector of Tamoxifen-Induced Apoptosis
Cancer Res., August 1, 2008; 68(15): 6387 - 6395.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. A. Thasni, S. Rakesh, G. Rojini, T. Ratheeshkumar, G. Srinivas, and S. Priya
Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 ovarian cancer cells in response to plumbagin and other chemotherapeutic agents
Ann. Onc., April 1, 2008; 19(4): 696 - 705.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
J.-M. Renoir, C. Bouclier, A. Seguin, V. Marsaud, and B. Sola
Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells
J. Mol. Endocrinol., March 1, 2008; 40(3): 101 - 112.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Cheng, D. V. Yu, J.-H. Zhou, and D. J. Shapiro
Tamoxifen Induction of CCAAT Enhancer-binding Protein {alpha} Is Required for Tamoxifen-induced Apoptosis
J. Biol. Chem., October 19, 2007; 282(42): 30535 - 30543.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Naderi, A. E. Teschendorff, J. Beigel, M. Cariati, I. O. Ellis, J. D. Brenton, and C. Caldas
BEX2 Is Overexpressed in a Subset of Primary Breast Cancers and Mediates Nerve Growth Factor/Nuclear Factor-{kappa}B Inhibition of Apoptosis in Breast Cancer Cell Lines
Cancer Res., July 15, 2007; 67(14): 6725 - 6736.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Sharma, N. K. Saxena, N. E. Davidson, and P. M. Vertino
Restoration of Tamoxifen Sensitivity in Estrogen Receptor-Negative Breast Cancer Cells: Tamoxifen-Bound Reactivated ER Recruits Distinctive Corepressor Complexes.
Cancer Res., June 15, 2006; 66(12): 6370 - 6378.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J A Vendrell, I Bieche, C Desmetz, E Badia, S Tozlu, C Nguyen, J C Nicolas, R Lidereau, and P A Cohen
Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines
Endocr. Relat. Cancer, March 1, 2005; 12(1): 75 - 92.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
D N Danforth Jr
All trans-retinoic acid acts synergistically with hydroxytamoxifen and transforming-growth factor {beta} to stimulate apoptosis in MCF-7 breast cancer cells
J. Endocrinol., November 1, 2004; 183(2): 395 - 404.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S.-Y. Sun, N. Hail Jr, and R. Lotan
Apoptosis as a Novel Target for Cancer Chemoprevention
J Natl Cancer Inst, May 5, 2004; 96(9): 662 - 672.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Tangkeangsirisin, J. Hayashi, and G. Serrero
PC Cell-Derived Growth Factor Mediates Tamoxifen Resistance and Promotes Tumor Growth of Human Breast Cancer Cells
Cancer Res., March 1, 2004; 64(5): 1737 - 1743.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Hur, J. Chesnes, K. R. Coser, R. S. Lee, P. Geck, K. J. Isselbacher, and T. Shioda
The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis
PNAS, February 24, 2004; 101(8): 2351 - 2356.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Thiantanawat, B. J. Long, and A. M. Brodie
Signaling Pathways of Apoptosis Activated by Aromatase Inhibitors and Antiestrogens
Cancer Res., November 15, 2003; 63(22): 8037 - 8050.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. M. W. Gee, M. E. Harper, I. R. Hutcheson, T. A. Madden, D. Barrow, J. M. Knowlden, R. A. McClelland, N. Jordan, A. E. Wakeling, and R. I. Nicholson
The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro
Endocrinology, November 1, 2003; 144(11): 5105 - 5117.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
L. Li, J. Backer, A. S. K. Wong, E. L. Schwanke, B. G. Stewart, and M. Pasdar
Bcl-2 expression decreases cadherin-mediated cell-cell adhesion
J. Cell Sci., September 15, 2003; 116(18): 3687 - 3700.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Buttitta, C. Pellegrini, A. Marchetti, A. Gadducci, S. Cosio, L. Felicioni, F. Barassi, S. Salvatore, C. Martella, G. Coggi, et al.
Human Telomerase Reverse Transcriptase mRNA Expression Assessed by Real-Time Reverse Transcription Polymerase Chain Reaction Predicts Chemosensitivity in Patients With Ovarian Carcinoma
J. Clin. Oncol., April 1, 2003; 21(7): 1320 - 1325.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Curigliano, M. Colleoni, G. Renne, G. Mazzarol, R. Gennari, G. Peruzzotti, F. de Braud, C. Robertson, E. Maiorano, P. Veronesi, et al.
Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay
Ann. Onc., June 1, 2002; 13(6): 895 - 902.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. J. Kottke, A. L. Blajeski, X. W. Meng, P. A. Svingen, S. Ruchaud, P. W. Mesner Jr., S. A. Boerner, K. Samejima, N. V. Henriquez, T. J. Chilcote, et al.
Lack of Correlation between Caspase Activation and Caspase Activity Assays in Paclitaxel-treated MCF-7 Breast Cancer Cells
J. Biol. Chem., January 4, 2002; 277(1): 804 - 815.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
A. Rebollo, V. Ayllon, A. Fleischer, C. Martinez-A., and A. Zaballos
The Association of Aiolos Transcription Factor and Bcl-xL Is Involved in the Control of Apoptosis
J. Immunol., December 1, 2001; 167(11): 6366 - 6373.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. W. Tong, M. H. Papayoti, G. Netto, D. T. Armstrong, G. Ordonez, J. M. Lawson, and M. J. Stone
Growth-inhibitory Effects of CD40 Ligand (CD154) and Its Endogenous Expression in Human Breast Cancer
Clin. Cancer Res., March 1, 2001; 7(3): 691 - 703.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
R. Stackievicz, L. Drucker, J. Radnay, Y. Beyth, S. Yarkoni, and I. Cohen
Tamoxifen Modulates Apoptotic Pathways in Primary Endometrial Cell Cultures
Clin. Cancer Res., February 1, 2001; 7(2): 415 - 420.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, G.-J.
Right arrow Articles by Takenoshita, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, G.-J.
Right arrow Articles by Takenoshita, S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online